Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
1.195
+0.025 (2.14%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Windtree Therapeutics Employees
Windtree Therapeutics had 20 employees as of December 31, 2022. The number of employees decreased by 13 or -39.39% compared to the previous year.
Employees
20
Change (1Y)
-13
Growth (1Y)
-39.39%
Revenue / Employee
n/a
Profits / Employee
-$274,350
Market Cap
4.30M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 20 | -13 | -39.39% |
Dec 31, 2021 | 33 | 2 | 6.45% |
Dec 31, 2020 | 31 | -1 | -3.13% |
Dec 31, 2019 | 32 | -1 | -3.03% |
Dec 31, 2018 | 33 | 5 | 17.86% |
Dec 31, 2017 | 28 | -21 | -42.86% |
Dec 31, 2016 | 49 | -9 | -15.52% |
Dec 31, 2015 | 58 | -52 | -47.27% |
Dec 31, 2014 | 110 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
WINT News
- 4 weeks ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 4 weeks ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 4 weeks ago - Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - GlobeNewsWire
- 5 weeks ago - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product - GlobeNewsWire
- 3 months ago - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - GlobeNewsWire
- 3 months ago - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - GlobeNewsWire
- 4 months ago - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia - GlobeNewsWire
- 5 months ago - Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction - GlobeNewsWire